OBJECTIVES: ATP-Binding Cassette (ABC) transporters may cause treatment failure by transporting of anticancer drugs outside of the tumor cells. Multidrug resistance-associated protein 1 coded by the ABCC1 gene has recently been suggested as a potential prognostic marker in breast cancer patients. This study aimed to explore tagged haplotype covering nucleotide binding domain 1 of ABCC1 in relation with corresponding transcript levels in tissues and clinical phenotype of breast cancer patients. METHODS: The distribution of twelve ABCC1 polymorphisms was assessed by direct sequencing in peripheral blood DNA (n = 540). RESULTS: Tumors from carriers of the wild type genotype in rs35623 or rs35628 exhibited significantly lower levels of ABCC1 transcript than those from carriers of the minor allele (p = 0.003 and p = 0.004, respectively). The ABCC1 transcript levels significantly increased in the order CT-GT>CC-GT>CC-GG for the predicted rs35626-rs4148351 diplotype. Chemotherapy-treated patients carrying the T allele in rs4148353 had longer disease-free survival than those with the GG genotype (p = 0.043). On the other hand, hormonal therapy-treated patients with the AA genotype in rs35628 had significantly longer disease-free survival than carriers of the G allele (p = 0.012). CONCLUSIONS: Taken together, our study shows that genetic variability in the nucleotide binding domain 1 has a significant impact on the ABCC1 transcript level in the target tissue and may modify survival of breast cancer patients.

Biolab Praha k s Prague Czech Republic

Department of Oncology Motol University Hospital Prague Czech Republic

Department of Radiotherapy and Oncology Faculty Hospital Kralovske Vinohrady Prague Czech Republic

Department of Toxicogenomics National Institute of Public Health Prague Czech Republic

Department of Toxicogenomics National Institute of Public Health Prague Czech Republic; 3rd Faculty of Medicine Charles University Prague Czech Republic

Department of Toxicogenomics National Institute of Public Health Prague Czech Republic; Department of Oncology Palacky University Medical School and Teaching Hospital Olomouc Czech Republic

Department of Toxicogenomics National Institute of Public Health Prague Czech Republic; Institute of Experimental Medicine Czech Academy of Sciences Prague Czech Republic

Institute for the Care for Mother and Child Prague Czech Republic

Institute of Experimental Medicine Czech Academy of Sciences Prague Czech Republic; Institute of Biology and Medical Genetics 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 (Internet). Lyon, France: International Agency for Research on Cancer, http://globocan.iarc.fr.

Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30: 1174–1184. PubMed

Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, et al. (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6: 129–137. PubMed

Ferguson LR, De Flora S (2005) Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutat Res 591: 24–33. PubMed

Liscovitch M, Lavie Y (2002) Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 349–355. PubMed

Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159–165. PubMed

Akan I, Akan S, Akca H, Savas B, Ozben T (2005) Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine. Cancer Cell International 5: 22. PubMed PMC

Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654. PubMed

Grant CE, Kurz EU, Cole SP, Deeley RG (1997) Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. Genomics 45: 368–378. PubMed

Cole SP (2014) Targeting Multidrug Resistance Protein 1 (MRP1, ABCC1): Past, Present, and Future. Annu Rev Pharmacol Toxicol 54: 95–117. PubMed

Hipfner DR, Deeley RG, Cole SP (1999) Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461: 359–376. PubMed

Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, et al. (2013) High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat 137: 773–782. PubMed PMC

Hlaváč V, Brynychová V, Václavíková R, Ehrlichová M, Vrána D, et al. (2013) The expression profile of ABC transporter genes in breast carcinoma. Pharmacogenomics 14: 515–529. PubMed

Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SP, et al. (2001) Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 46: 656–663. PubMed

Oselin K, Mrozikiewicz PM, Gaikovitch E, Pahkla R, Roots I (2003) Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 59: 347–350. PubMed

Wang Z, Wang B, Tang K, Lee EJD, Chong SS, et al. (2005) A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum Mol Genet 14: 2075–2087. PubMed

Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, et al. (2013) Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving neo-adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 24: 1513–1525. PubMed

Conrad S, Kauffmann HM, Ito K, Leslie EM, Deeley RG, et al. (2002) A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12: 321–330. PubMed

Leslie EM, Létourneau IJ, Deeley RG, Cole SP (2003) Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 42: 5214–5224. PubMed

Yin J-Y, Huang Q, Yang Y, Zhang J-T, Zhong M-Z, et al. (2009) Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 19: 206–216. PubMed PMC

Brynychová V, Hlaváč V, Ehrlichová M, Václavíková R, Pecha V, et al. (2013) Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression. Future Oncol 9: 427–438. PubMed

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, et al. (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736–1747. PubMed PMC

Topic E, Gluhak J (1991) Isolation of restrictible DNA. Eur J Clin Chem Clin Biochem 29: 327–330. PubMed

Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps Bioinformatics. 21: 263–265. PubMed

Untergrasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, et al. (2012) Primer3 - new capabilities and interfaces. Nucleic Acids Res 40: e115. PubMed PMC

Soucek P, Anzenbacher P, Skoumalova I, Dvorak M (2005) Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells. Stem Cells 23: 1417–1422. PubMed

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al. (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611–622. PubMed

Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al. (2002) The structure of haplotype blocks in the human genome. Science 296: 2225–2229. PubMed

Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B 57: 289–300.

Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219–234. PubMed

Gao M, Cui HR, Loe DW, Grant CE, Almquist KC, et al. (2000) Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. J Biol Chem 275: 13098–13108. PubMed

Qin L, Zheng J, Grant CE, Jia Z, Cole SP, et al. (2008) Residues responsible for the asymmetric function of the nucleotide binding domains of multidrug resistance protein 1. Biochemistry 47: 13952–13965. PubMed

Iram SH, Cole SP (2011) Expression and function of human MRP1 (ABCC1) is dependent on amino acids in cytoplasmic loop 5 and its interface with nucleotide binding domain 2. J Biol Chem 286: 7202–7213. PubMed PMC

Ramaen O, Leulliot N, Sizun C, Ulryck N, Pamlard O, et al. (2006) Structure of the human multidrug resistance protein 1 nucleotide binding domain 1 bound to Mg2+/ATP reveals a non-productive catalytic site. J Mol Biol 359: 940–949. PubMed

Rungsardthong K, Mares-Sámano S, Penny J (2012) Virtual screening of ABCC1 transporter nucleotidebinding domains as a therapeutic target in multidrug resistant cancer. Bioinformation 8: 907–911. PubMed PMC

Vaclavikova R, Nordgard SH, Alnaes GIG, Hubackova M, Kubala E, et al. (2008) Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics 18: 263–273. PubMed

Kim B, Fatayer H, Hanby AM, Horgan K, Perry SL, et al. (2013) Neoadjuvant Chemotherapy Induces Expression Levels of Breast Cancer Resistance Protein That Predict Disease-Free Survival in Breast Cancer. PLoS ONE 8: e62766. PubMed PMC

Filipits M, Pohl G, Rudas M, Dietze O, Lax S, et al. (2005) Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 23: 1161–1168. PubMed

McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE (2011) From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med 5: 795–806. PubMed PMC

Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, et al. (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21: 440–446. PubMed PMC

Teft WA, Mansell SE, Kim RB (2011) Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab. Dispos 39: 558–562. PubMed

Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H (2012) Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet 27: 122–131. PubMed

Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, et al. (2013) Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat 140: 63–71. PubMed PMC

Letourneau IJ, Deeley RG, Cole SP (2005) Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics 15: 647–657. PubMed

Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248–249. PubMed PMC

Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073–1081. PubMed

Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, et al. (2012) Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 22: 1790–1797. PubMed PMC

Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, et al. (2005) Mapping determinants of human gene expression by regional and genome-wide association. Nature. 437: 1365–1369. PubMed PMC

Marchler-Bauer A, Lu S, Anderson JB, Chitsaz F, Derbyshire MK, et al. (2011) CDD: a Conserved Domain Database for the functional annotation of proteins. Nucleic Acids Res 39: D225–229. PubMed PMC